162 related articles for article (PubMed ID: 27330257)
1. Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients.
Kovačević T; Avram S; Milaković D; Špirić N; Kovačević P
J Basic Clin Pharm; 2016 Jun; 7(3):65-9. PubMed ID: 27330257
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of amikacin in noncritically ill patients
.
Kim DJ; Lee J; Yu H; Lee DH; Kang T; Han YK; Kim DH; Kim SW
Clin Nephrol; 2019 Oct; 92(4):201-207. PubMed ID: 31347498
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients.
Hodiamont CJ; Janssen JM; de Jong MD; Mathôt RA; Juffermans NP; van Hest RM
Ther Drug Monit; 2017 Oct; 39(5):522-530. PubMed ID: 28682925
[TBL] [Abstract][Full Text] [Related]
4. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Roger C; Nucci B; Louart B; Friggeri A; Knani H; Evrard A; Lavigne JP; Allaouchiche B; Lefrant JY; Roberts JA; Muller L
J Antimicrob Chemother; 2016 Jan; 71(1):208-12. PubMed ID: 26429564
[TBL] [Abstract][Full Text] [Related]
5. Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients.
Abdel-Bari A; Mokhtar MS; Sabry NA; El-Shafi SA; Bazan NS
Saudi Pharm J; 2011 Jan; 19(1):9-17. PubMed ID: 23960738
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
[TBL] [Abstract][Full Text] [Related]
7. Gentamicin dosing in critically ill patients.
Hansen M; Christrup LL; Jarløv JO; Kampmann JP; Bonde J
Acta Anaesthesiol Scand; 2001 Jul; 45(6):734-40. PubMed ID: 11421832
[TBL] [Abstract][Full Text] [Related]
8. Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen.
Ben Romdhane H; Ben Fredj N; Chaabane A; Ben Aicha S; Chadly Z; Ben Fadhel N; Boughattas N; Aouam K
Nephrol Ther; 2019 Apr; 15(2):110-114. PubMed ID: 30660586
[TBL] [Abstract][Full Text] [Related]
9. Standards of aminoglycoside therapeutic drug monitoring in a South African private hospital: perspectives and implications.
du Toit M; Burger JR; Rakumakoe DM; Rheeders M
Ghana Med J; 2019 Mar; 53(1):8-12. PubMed ID: 31138938
[TBL] [Abstract][Full Text] [Related]
10. Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
Roger C; Nucci B; Molinari N; Bastide S; Saissi G; Pradel G; Barbar S; Aubert C; Lloret S; Elotmani L; Polge A; Lefrant JY; Roberts JA; Muller L
Int J Antimicrob Agents; 2015 Jul; 46(1):21-7. PubMed ID: 25857948
[TBL] [Abstract][Full Text] [Related]
11. Aminoglycoside usage and monitoring in a Saudi Arabian teaching hospital: a ten-year laboratory audit.
Adjepon-Yamoah KK; Al-Homrany M; Bahar Y; Ahmed ME
J Clin Pharm Ther; 2000 Aug; 25(4):303-7. PubMed ID: 10971782
[TBL] [Abstract][Full Text] [Related]
12. Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
Duong A; Thirion DJG; Williamson D; Simard C; Marsot A
J Chemother; 2022 Sep; 34(5):341-344. PubMed ID: 35238282
[TBL] [Abstract][Full Text] [Related]
13. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis.
Hodiamont CJ; Juffermans NP; Bouman CS; de Jong MD; Mathôt RA; van Hest RM
Int J Antimicrob Agents; 2017 Feb; 49(2):204-211. PubMed ID: 28038961
[TBL] [Abstract][Full Text] [Related]
14. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring of aminoglycosides in acute myeloid leukaemia patients.
Mareville J; Gay J; Cliquennois E; Herbaux C; Pasquier F; Allorge D; Blondiaux N; Berthon C; Alfandari S
Scand J Infect Dis; 2012 May; 44(5):398-401. PubMed ID: 22235869
[TBL] [Abstract][Full Text] [Related]
16. Limited sampling strategy for estimation of amikacin optimal sampling time in critically ill adults.
Mahmoudi L; Mohammadpour AH; Niknam R; Ahmadi A; Mojtahedzdeh M
Anaesth Intensive Care; 2014 Mar; 42(2):228-33. PubMed ID: 24580389
[TBL] [Abstract][Full Text] [Related]
17. High-dose amikacin for achieving serum target levels in critically ill elderly patients.
Sadeghi K; Hamishehkar H; Najmeddin F; Ahmadi A; Hazrati E; Honarmand H; Mojtahedzadeh M
Infect Drug Resist; 2018; 11():223-228. PubMed ID: 29483780
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.
Velissaris D; Karamouzos V; Marangos M; Pierrakos C; Karanikolas M
J Clin Med Res; 2014 Aug; 6(4):227-33. PubMed ID: 24883145
[TBL] [Abstract][Full Text] [Related]
19. Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood.
Al-Aqbi ZT; Yap YC; Li F; Breadmore MC
Biosensors (Basel); 2019 Jan; 9(1):. PubMed ID: 30704056
[TBL] [Abstract][Full Text] [Related]
20. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Zavascki AP; Klee BO; Bulitta JB
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
